Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01982591 · ClinicalTrials.gov registry record
Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
A clinical trial, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- 115
- Enrollment target
NCT01982591: Completed study, sponsored by Fox Chase Cancer Center.
NCT01982591 is a clinical trial that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 115 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01982591 has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- 115 participants
- Enrollment target
Study Summary
This research trial studies heavy metal exposure in predicting peripheral neuropathy in patients with stage I-III breast cancer undergoing chemotherapy. Studying samples of blood and urine in the laboratory for heavy metal exposure from patients receiving chemotherapy may help doctors find out whether side effects from chemotherapy are related to heavy metal exposure.
Primary Outcome
Heavy metal levels will be characterized in participants being treated at participating sites. Means and variances and ranges of these levels will be tabulated.
Interventions
- OTHER laboratory biomarker analysis
- OTHER questionnaire administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2011-01-03 |
| Est. Completion | 2015-03-24 |
What the finished NCT01982591 record still lists
NCT01982591 is an observational study that tracks outcomes without assigning an intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT01982591 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01982591 about?
NCT01982591 is a clinical study titled "Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy". This research trial studies heavy metal exposure in predicting peripheral neuropathy in patients with stage I-III breast cancer undergoing chemotherapy. Studying samples of blood and urine in the laboratory for heavy metal exposure from patients receiving chemotherapy may help doctors find out wheth...
What is the current status of trial NCT01982591?
This trial is currently completed. The enrollment target is 115 participants. The study started on 2011-01-03. Estimated completion is 2015-03-24.
What interventions are being tested in trial NCT01982591?
The interventions under investigation include: laboratory biomarker analysis (OTHER), questionnaire administration (OTHER).
Who is sponsoring clinical trial NCT01982591?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02346929 · 115 participants · NA
Hematoma Block for Distal Radius Fracture
- NCT03394365 · 115 participants · Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- NCT03907475 · 115 participants · Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- NCT05086692 · 115 participants · Phase 1
A Beta-only IL-2 ImmunoTherapY Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI